Vaxcyte Inc reports results for the quarter ended in March - Earnings Summary

Vaxcyte

09/05/2024 18:59

* Vaxcyte Inc  PCVX.OQ  reported a quarterly adjusted loss
of 85
cents​​ per share for the quarter ended in March, lower than the
same quarter last year, when the company reported EPS of -70
cents.  The mean expectation of nine analysts for the quarter
was for a loss of $1.17 per share. Wall Street expected
results to range from $-1.72 to -84 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Vaxcyte Inc's reported EPS for the quarter was a loss
of 85
cents​.
    * The company reported a quarterly loss of $95.02 million.
    * Vaxcyte Inc shares had fallen by 2.2% this quarter and
gained 6.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 12.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Vaxcyte Inc is
$102.00 
This summary was machine generated from LSEG data May 9 at 05:59
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.17          -0.85          Beat
 Dec. 31 2023      -1.07          -1.82          Missed
 Sep. 30 2023      -0.84          -0.91          Missed
 Jun. 30 2023      -0.74          -0.70          Beat